Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling ...

EQS-News: Eckert & Ziegler SE / Key word(s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 ...

Detailed price information for Defence Therapeutics Inc (DTCFF) from The Globe and Mail including charting and trades.

This publication includes existing experiences, lessons learned, challenges and future developments in the production of Ac-225 radiopharmaceuticals for Targeted Alpha Therapy (TAT). This publication ...

As anticipated, we have seen robust tumor control and ATNM-400 has shown to be well tolerated in preclinical studies, which we believe is due to the precise and potent cell-killing of Ac-225.

CNL, Canada's premier nuclear science facility, will conduct preclinical studies combining alpha-particle radiotherapy Actinium-225 ("Ac-225") with Defence's proprietary Accum ® delivery technology.

Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under ...